Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06288516
Other study ID # 7484
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 1, 2024
Est. completion date June 1, 2026

Study information

Verified date March 2024
Source Aristotle University Of Thessaloniki
Contact Kalliopi Domvri, Dr
Phone 00306940904246
Email kdomvrid@auth.gr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Response to biologic therapies in severe asthma is variable, with patients being either non-responders, responders or super-responders. There is currently no explanation for this broad variation in response. It is important to examine whether these patients have distinct characteristics that could help the treating physician in making the correct diagnosis in clinical practice. Aim of this clinical study is to evaluate the efficacy of benralizumab, a humanized an anti-interleukin 5 receptor α monoclonal antibody in patients with severe eosinophilic asthma and to evaluate airway remodeling before and after benralizumab treatment. Hypothesis Identification of pathological and clinical characteristics in patients with severe eosinophilic asthma after benralizumab treatment regarding the airway remodeling, inflammatory cells, and other biomarkers on a long-term basis. Research questions Is there any improvement in airway remodeling? Are there any biomarkers to predict response to benralizumab treatment in severe eosinophilic asthmatic patients?


Description:

Interleukin (IL)-5 is the main cytokine responsible for the activation of eosinophils, hence therapeutic strategies have been investigated and developed for clinical use. Biologics targeting IL-5 and its receptor have been recently approved and used as add-on therapy for severe eosinophilic asthma resulting in a reduction in the circulating eosinophil count, improvement in lung function and exacerbation reduction in patients with severe asthma. Response to biologic therapies in severe asthma is variable, with patients being either non-responders, responders or super-responders. There is currently no explanation for this broad variation in response. It is important to examine whether these patients have distinct characteristics that could help the treating physician in making the correct diagnosis in clinical practice. Aim of this clinical study is to evaluate the efficacy of benralizumab, a humanized an anti-interleukin 5 receptor α monoclonal antibody in patients with severe eosinophilic asthma and to evaluate airway remodeling before and after benralizumab treatment. Every patient will be a control to himself by comparing baseline's biomarker measurements of each patient to the following timepoint's measurements. However, we have added 10 severe asthmatics with no intervention, receiving standard of care as control groups to make more comparisons. Several methods are used to investigate airway inflammation: direct measurements (like bronchial biopsies or bronchoalveolar lavages) and indirect methods (like symptom assessment, blood sample analysis and lung function tests). The direct techniques have the advantage of reliably assessing the airway inflammation, but they are invasive and not feasible at large scale because of patient discomfort and the risk incurred. As for the indirect methods, they poorly correlate with the direct assessment of airway inflammation. In this study, among patients' clinical characteristics spirometry, biomarkers of inflammation such as blood eosinophils, Fractional Exhaled Nitric Oxide (FeNO), immunoglobulin E (IgE) levels), and airway remodeling via bronchoscopy will be evaluated. The precise effects of increased airway smooth muscle area on airway narrowing are not known and may vary with disease severity. In addition, biomarkers of inflammation will also be evaluated before and after 52-week of benralizumab treatment in biological fluids (serum and bronchial samples). Biomarkers of inflammation are very important to identify treatment response. Besides, asthmatic disease is characterized by a chronic mucosal inflammatory process, which results in irreversible changes of the bronchial wall, known today as "bronchial remodeling". Glandular and smooth muscle fibers hyperplasia and/or hypertrophy, goblet cells hyperplasia, and variable thickening of basement membrane (BM) present under the respiratory epithelium are part of these morphological changes. the changes generated at the epithelium-connective interface account for an "adaptive response" to inflammatory stress and sporadic bronchoconstriction. However, current data on BM reactivity in asthmatic patient are still incomplete for an accurate assessment of its involvement in pathogenesis and specifically in bronchial wall remodeling, mainly as collagen deposits in lamina reticularis are not correlated to the degree of disease severity. Moreover, it is increasingly evident that severe asthma is not a single disease, as evidenced by the variety of clinical presentations, physiologic characteristics, and outcomes seen in patients with asthma. To better understand this heterogeneity, the concept of asthma phenotyping and endotyping has emerged. Phenotyping integrates both biological and clinical features, from molecular, cellular, morphologic, and functional to patient-oriented characteristics with the goal to improve therapy. Ultimately, these phenotypes evolve into asthma "endotypes," which combine clinical characteristics with identifiable mechanistic pathways. Biomarkers, defined as characteristics that can be objectively measured and serve as an indicator of underlying biological processes or pathogenesis, are crucial in defining phenotypes and endotypes. In asthma, genetic polymorphisms, measures of airway physiology, and levels of inflammatory mediators in urine, blood, sputum, tissue, exhaled gas, and breath condensate have all been studied as potential markers to improve and objectify asthma diagnosis and management. Developing such tools will allow us to phenotype and endotype the various clinical patterns described in asthma, with the ultimate goal of tailoring therapy based on a specific biomarker profile. Biomarkers can then be used to help better understand the pharmacologic response to an intervention and adjust therapy accordingly. Biomarkers have been critical for studies of disease pathogenesis and the development of new therapies in severe asthma. In particular, biomarkers of type 2 inflammation have proven valuable for endotyping and targeting new biological agents. Because of these successes in understanding and marking type 2 inflammation, lack of knowledge regarding non-type 2 inflammatory mechanisms in asthma will soon be the major obstacle to the development of new treatments and management strategies in severe asthma. Other potential biomarkers include innate lymphoid cells, IL-33 or thymic stromal lymphopoietin.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date June 1, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Written informed consent must be obtained at screening visit, before any assessment will be performed. Subjects should be able to provide informed written consent (study participation informed consent form): Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Subjects must be able to read, comprehend, and write at a level sufficient to complete study related materials. - Confirmed severe asthma diagnosis and treatment requirements according to American Thoracic Society(ATS)/European Respiratory Society (ERS) guidelines and Global Initiative for Asthma (GINA) 2023. - Blood eosinophils =150cells/ul at screening visit or =300cells/ul the last 12 months. - Patients with history = 1 exacerbation the previous year under the treatment of high dose of inhaled corticosteroid(ICS)+LABA±LAMA or receiving oral/systemic corticosteroids at least 3 days. For subjects on maintenance oral corticosteroids, an exacerbation requiring oral corticosteroids was defined as the use of oral/systemic corticosteroids at least double the existing dose for at least 3 days. - Meet requirements for biologic therapy with Benralizumab. Exclusion Criteria: - Asthma exacerbation, within 6 weeks prior to screening that required hospitalization or emergency room visit. - Prior use of other biologics that has potential to interfere/ affect disease progression. - Pregnant or nursing women, or women of child-bearing potential. - History of malignancy of any organ system or any other serious co-morbidities defined by the treating physician. - Patients with a history of conditions other than asthma that could result in elevated eosinophils (e.g. hypereosinophilic syndromes, Churg-Strauss Syndrome, eosinophilic esophagitis).

Study Design


Intervention

Drug:
Benralizumab 30 mg/ml
Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks

Locations

Country Name City State
Greece Pulmonary Clinic, Aristotle University of Thessaloniki, George Papanikolaou Hospital Thessaloniki

Sponsors (8)

Lead Sponsor Collaborator
Aristotle University Of Thessaloniki 2nd Pulmonary Clinic, Kapodistrian University of Athens, Pulmonary and Respiratory Failure Department, National and Kapodistrian University of Athens, Pulmonary Clinic, Aristotle University of Thessaloniki, Greece, Pulmonary Clinic, Democritus University of Thrace, Pulmonary Clinic, University of Ioannina, University Hospital of Crete, University Hospital of Patras

Country where clinical trial is conducted

Greece, 

References & Publications (6)

Bara I, Ozier A, Tunon de Lara JM, Marthan R, Berger P. Pathophysiology of bronchial smooth muscle remodelling in asthma. Eur Respir J. 2010 Nov;36(5):1174-84. doi: 10.1183/09031936.00019810. — View Citation

Berair R, Hartley R, Mistry V, Sheshadri A, Gupta S, Singapuri A, Gonem S, Marshall RP, Sousa AR, Shikotra A, Kay R, Wardlaw A, Bradding P, Siddiqui S, Castro M, Brightling CE. Associations in asthma between quantitative computed tomography and bronchial — View Citation

Kuo CW, Liao XM, Huang YC, Chang HY, Shieh CC. Bronchoscopy-guided bronchial epithelium sampling as a tool for selecting the optimal biologic treatment in a patient with severe asthma: a case report. Allergy Asthma Clin Immunol. 2019 Nov 27;15:76. doi: 10 — View Citation

Rasmussen F, Taylor DR, Flannery EM, Cowan JO, Greene JM, Herbison GP, Sears MR. Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: a longitudinal population study from childhood to adulthood. Am — View Citation

Siddiqui S, Bachert C, Bjermer L, Buchheit KM, Castro M, Qin Y, Rupani H, Sagara H, Howarth P, Taille C. Eosinophils and tissue remodeling: Relevance to airway disease. J Allergy Clin Immunol. 2023 Oct;152(4):841-857. doi: 10.1016/j.jaci.2023.06.005. Epub — View Citation

Yancey SW, Keene ON, Albers FC, Ortega H, Bates S, Bleecker ER, Pavord I. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017 Dec;140(6):1509-1518. doi: 10.1016/j.jaci.2017.10.005. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in sub-basement membrane thickness The identification of clinical characteristics of non-responders and super-responders. Any improvement in this parameter will be measured as change from baseline compared to measurement after 1 year of treatment. through study completion, 52 weeks
Primary Change in airway smooth muscle area The identification of clinical characteristics of non-responders and super-responders. Any improvement in this parameter will be measured as change from baseline compared to measurement after 1 year of treatment. through study completion, 52 weeks
Primary Change in airway smooth muscle layer thickness The identification of clinical characteristics of non-responders and super-responders. Any improvement in this parameter will be measured as change from baseline compared to measurement after 1 year of treatment. through study completion, 52 weeks
Primary Change in submucosal eosinophil number The identification of clinical characteristics of non-responders and super-responders. Any improvement in this parameter will be measured as change from baseline compared to measurement after 1 year of treatment. through study completion, 52 weeks
Primary Change in epithelial integrity The identification of clinical characteristics of non-responders and super-responders. Any improvement in this parameter will be measured as change from baseline compared to measurement after 1 year of treatment. through study completion, 52 weeks
Primary Change in collagen thickness The identification of clinical characteristics of non-responders and super-responders. Any improvement in this parameter will be measured as change from baseline compared to measurement after 1 year of treatment, measured by electron microscopy. through study completion, 52 weeks
Secondary Change of cytokine and protein levels To identify any possible biomarkers of response of non-responders versus super-responders in different biological fluids as peripheral blood and bronchial washing. The identification of clinical characteristics of non-responders and super-responders.
Change from baseline compared to measurements after 6 months and after 1 year of benralizumab treatment.
through study completion, 52 weeks
Secondary Change in exacerbation rate Measurement of the change in exacerbation rate in each severe eosinophilic asthmatic patient under benralizumab treatment for 52 weeks of treatment. through study completion, 52 weeks
Secondary Change in blood eosinophil levels Measurement of the change in blood eosinophil levels in each severe eosinophilic asthmatic patient under benralizumab treatment for 52 weeks of treatment. through study completion, 52 weeks
Secondary dentification of clinical characteristics of response, change in Forced Expiratory Volume (FEV1) The identification of clinical characteristics of non-responders and super-responders. FEV1 change from baseline, before treatment initiation, compared to measurements every 3 months until 1 year of treatment. FEV1 is the maximal amount of air you can forcefully exhale in one second measured by spirometry. through study completion, 52 weeks
See also
  Status Clinical Trial Phase
Completed NCT04742504 - Interaction Between Benralizumab and Basophils in Eosinophilic Asthma
Recruiting NCT04565483 - Predictive Signature of Benralizumab Response Phase 4
Completed NCT04181190 - Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients
Recruiting NCT05787678 - Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion
Completed NCT04456270 - Asthma Control in a Dutch Primary Care Population
Not yet recruiting NCT05091385 - Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
Recruiting NCT05078281 - Patients With Severe Eosinophilic Asthma Treated With Benralizumab
Recruiting NCT04512521 - Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma
Recruiting NCT05813288 - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Phase 3
Recruiting NCT04319705 - Anti-viral Effects of Azithromycin in Patients With Asthma and COPD Phase 4
Active, not recruiting NCT03733535 - Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI N/A
Not yet recruiting NCT05241769 - The Influence of Inhaled CorticoSteroids Adherence on Treatment Response to Mepolizumab in Severe Eosinophilic Asthma
Not yet recruiting NCT04924478 - Evaluation of Volatile Organic Compounds in Mepolizumab Therapy
Recruiting NCT05748600 - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma Phase 3
Recruiting NCT05763121 - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. Phase 3
Completed NCT03453021 - Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma
Active, not recruiting NCT04612556 - Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)
Recruiting NCT05404763 - Mepolizumab and Physical Activity in Severe Asthma
Completed NCT04710134 - Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma Phase 4
Not yet recruiting NCT05144087 - The Influence of Mepolizumab on Structural and Inflammatory Cells in Severe Eosinophilic Asthma